Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Amicus Takes Over GSK’s Orphan Status for Migalastat for Fabry’s Disease
April 18, 2017
- Review of 14-Day Prescription Limit Up for Chuikyo Discussion Again
April 18, 2017
- AMED to Launch Portal Site to Promote Use of Biobanks as Part of Effort to Support Genomic Medicine
April 18, 2017
- With Clinical Research Law Enacted, MHLW Eyes New Panel to Discuss Requirements for “Specified Clinical Research”: R&D Division Head
April 17, 2017
- Japan, South Korea to Hold 2nd Joint Regulation Symposium in May
April 17, 2017
- Clinical Research Law Promulgated
April 17, 2017
- MHLW Never Pressured Bayer on Announcement Timing for Xarelto Issue: Official
April 14, 2017
- Tokyo Govt Orders 2 “Cash-and-Carry” Dealers to Suspend Business
April 14, 2017
- Pricing Debate Timeline Updated, with 3 Hearing Sessions Now Planned
April 13, 2017
- CEFP Setting Sights on Drug Pricing, High-Cost Benefit System
April 13, 2017
- Opdivo’s Optimal Use Guidelines for RCC, Hodgkin’s Lymphoma to Take Effect on April 18
April 13, 2017
- Scrutinize Specific Process of Cost-Based Drug Pricing: Chuikyo Subcommittee
April 13, 2017
- Post-Launch Price Correction Floated for Imported Drugs 1st Approved in Japan: Chuikyo
April 13, 2017
- Average Price of Drugs Prescribed to Outpatients Rising Due to Increase in Number of High-Priced Drugs: CEFP Working Group
April 13, 2017
- Rebates, Allowances Come Up in CEFP Social Security Working Group’s Analysis of Current State of Wholesalers
April 13, 2017
- Xarelto Survey Scandal “Very Regrettable”: Shiozaki
April 12, 2017
- CEFP Social Security Working Group Raises Questions on Price Maintenance Premium, Biosimilar Policy
April 12, 2017
- MHLW to Continue Withholding HPV Vaccine Recommendation
April 11, 2017
- 41 New APIs Approved in FY2016 in Japan: PMDA
April 11, 2017
- MHLW Advisory Panel to Review Mundipharma’s Injectable Pralatrexate on April 21
April 11, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…